Why Is BIOHAVEN LTD (BHVN) Stock Down Today?

BHVN stock is down 6.90% at $15.78 in a volatile session marked by early losses and a sharp decline after mid-morning. The move follows a mixed set of developments including a licensing deal with SK Biopharmaceuticals, a $4 million trade secret ruling, and revised analyst price targets. The stock opened lower and continued to fall through the morning as volume increased well above its recent average.

What Happened

Biohaven’s stock began the session with a 1.1% gap down from the previous close of $16.95, opening at $16.76. The stock briefly touched a high of $17.30 in early trading but quickly reversed course. By 9:45 AM ET, the stock had fallen to $15.50, its lowest point of the session. The decline came amid a flurry of analyst activity. Raymond James cut its price target from $50 to $30, citing asset monetization concerns, while TD Cowen maintained a Buy rating following the SK Biopharmaceuticals licensing deal. The mixed analyst sentiment contributed to the stock’s downward momentum.

The licensing agreement with SK Biopharmaceuticals granted exclusive worldwide rights to Biohaven’s Kv7 platform and its lead epilepsy drug, opakalim, for up to $795 million. While this deal was seen as a significant milestone, H.C. Wainwright noted it was a temporary reprieve rather than a long-term solution. Meanwhile, a $4 million ruling in favor of Biohaven and Yale University over a trade secret misappropriation case added a positive note but failed to offset the broader sell-off.

What The Data Shows

The stock traded at 0.3 times its 3-month average volume, with 0.9 million shares changing hands so far. Biohaven remains unprofitable with an EPS of -4.48 over the trailing twelve months and a high beta of 3.16. The stock is currently trading within its 52-week range of $7.48 to $18.57. On August 27, the 52-week tape showed 62 fresh 52-week highs and 18 fresh 52-week lows, indicating a broader market environment of mixed momentum.

What To Watch

Retail traders are now focused on the obesity trial readout, which could provide the next catalyst for Biohaven’s stock. Investors should also monitor the breadth of analyst coverage and any further developments from ongoing legal or licensing activities.